Head-To-Head Review: Geovax Labs (GOVX) & The Competition

Geovax Labs (OTCMKTS: GOVX) is one of 32 public companies in the “Commercial physical research” industry, but how does it compare to its rivals? We will compare Geovax Labs to similar businesses based on the strength of its institutional ownership, earnings, analyst recommendations, valuation, profitability, risk and dividends.

Profitability

This table compares Geovax Labs and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Geovax Labs -319.03% N/A -433.76%
Geovax Labs Competitors -281.45% -85.75% -34.41%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Geovax Labs and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Geovax Labs 0 0 0 0 N/A
Geovax Labs Competitors 125 591 1364 55 2.63

As a group, “Commercial physical research” companies have a potential upside of 14.32%. Given Geovax Labs’ rivals higher probable upside, analysts plainly believe Geovax Labs has less favorable growth aspects than its rivals.

Insider & Institutional Ownership

0.1% of Geovax Labs shares are owned by institutional investors. Comparatively, 47.1% of shares of all “Commercial physical research” companies are owned by institutional investors. 2.1% of Geovax Labs shares are owned by company insiders. Comparatively, 16.4% of shares of all “Commercial physical research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Geovax Labs and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Geovax Labs $1.08 million -$2.17 million -0.67
Geovax Labs Competitors $968.26 million $63.67 million 12.57

Geovax Labs’ rivals have higher revenue and earnings than Geovax Labs. Geovax Labs is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Geovax Labs has a beta of 0.1, suggesting that its share price is 90% less volatile than the S&P 500. Comparatively, Geovax Labs’ rivals have a beta of 4.22, suggesting that their average share price is 322% more volatile than the S&P 500.

Summary

Geovax Labs rivals beat Geovax Labs on 9 of the 10 factors compared.

Geovax Labs Company Profile

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines for infectious diseases and cancer in the United States and internationally. The company through its patented Modified Vaccinia Ankara-Virus Like Particle vaccine platform develops various vaccines. It is developing various vaccines that are in human clinical trials, and preclinical research and development phases, including vaccines against human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; United States Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; Peking University; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies, Inc.; Viamune, Inc.; Vaxeal Holding SA; and CaroGen Corporation. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.

Receive News & Ratings for Geovax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geovax Labs and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply